Baseline characteristics across the total cohort and stratified by mortality-risk profile
| Characteristic | No. (%)* | |||||||
|---|---|---|---|---|---|---|---|---|
| Total cohort n = 247 377 | Predicted median survival < 3 mo n = 2495 | Predicted median survival 3–6 mo n = 3700 | Predicted median survival 6–12 mo n = 8855 | Predicted mortality risk 20%–33% n = 19 949 | Predicted mortality risk 10%–20% n = 57 935 | Predicted mortality risk 5%–10% n = 86 558 | Predicted mortality risk < 5% n = 67 885 | |
| Age, mean ± SD | 80.07 ± 10.95 | 84.29 ± 9.86 | 83.73 ± 10.16 | 84.09 ± 10.05 | 83.83 ± 9.97 | 82.71 ± 10.13 | 80.46 ± 10.37 | 75.34 ± 11.16 |
| Sex | ||||||||
| Female | 153 127 (61.9) | 959 (38.4) | 1443 (39.0) | 3595 (40.6) | 8918 (44.7) | 30 256 (52.2) | 54 510 (63.0) | 53 446 (78.7) |
| Male | 94 250 (38.1) | 1536 (61.6) | 2257 (61.0) | 5260 (59.4) | 11 031 (55.3) | 27 679 (47.8) | 32 048 (37.0) | 14 439 (21.3) |
| Reason for assessment | ||||||||
| First assessment | 174 827 (70.7) | 1705 (68.3) | 2531 (68.4) | 6243 (70.5) | 14 213 (71.2) | 41 794 (72.1) | 62 308 (72.0) | 46 033 (67.8) |
| Routine reassessment | 61 284 (24.8) | 286 (11.5) | 543 (14.7) | 1385 (15.6) | 3602 (18.1) | 12 472 (21.5) | 21 762 (25.1) | 21 234 (31.3) |
| Discharge assessment or discharge tracking | 63 (0) | 1–5† | 1–5† | 5–9† | 18 (0.1) | 16 (0) | 12 (0) | 7 (0) |
| Clinically significant change in status reassessment | 10 787 (4.4) | 497 (19.9) | 616 (16.6) | 1193 (13.5) | 2064 (10.3) | 3527 (6.1) | 2341 (2.7) | 549 (0.8) |
| Other (e.g., research) | 416 (0.2) | 1–5† | 5–9† | 28 (0.3) | 52 (0.3) | 126 (0.2) | 135 (0.2) | 62 (0.1) |
| Year of assessment | ||||||||
| 2018 | 113 403 (45.8) | 1573 (63.0) | 2149 (58.1) | 5117 (57.8) | 11 258 (56.4) | 30 073 (51.9) | 39 802 (46.0) | 23 431 (34.5) |
| 2019 | 133 974 (54.2) | 922 (37.0) | 1551 (41.9) | 3738 (42.2) | 8691 (43.6) | 27 862 (48.1) | 46 756 (54.0) | 44 454 (65.5) |